2011 Accepted Abstracts
|
Please note that abstracts have not been edited by PAINWeek staff for content, style, or accuracy, and are displayed as input by each submitter. |
| 1. Open-label, open-ended study of the safety of diclofenac sodium topical solution for management of osteoarthritis: characterization of gastrointestinal adverse events Charles Argoff1, Jeff Patrick2, Zev Shainhouse3 1Albany Medical College, Albany, NY, USA, 2Covidien, Hazelwood, MO, USA, 3Consultant, Toronto, ON, Canada |
| 2. Open-label, open-ended study of the safety of diclofenac sodium topical solution for management of osteoarthritis: characterization of application-site adverse events Zev Shainhouse1, Jeff Patrick2, Charles Argoff3 1Consultant, Toronto, ON, Canada, 2Covidien, Hazelwood, MO, USA, 3Albany Medical College, Albany, NY, USA |
| 3. Evaluation of the current practices for managing postoperative pain and characterization of patients undergoing total knee or hip arthroplasty in a real-world setting Carmen Kirkness1,5, Carrie McAdam-Marx2, Sudhir Unni2, Jason Young2, Xiangyang Ye2, Arthi Chandran4, Da-In Kim4, Junji Lin2, Christopher Peters3, Carl Asche2,5 1Department of Physical Therapy, College of Health, University of Utah, Salt Lake City, UTAH, USA, 2Department of Pharmacotherapy, University of Utah, Salt Lake City, UTAH, USA, 3Department of Orthopaedics, School of Medicine, University of Utah, Salt Lake City, UTAH, USA, 4Pfizer, Inc., New York, NEW YORK, USA, 5University of Illinois College of Medicine, Peoria, ILLINOIS, USA |
| 4. Observation of improved adherence with ongoing urine drug testing in patients with chronic pain David Yee1, Michelle Hughes1, Alexander Guo1, Stephanie Tse1, Neveen Barakat1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA, 2Doris A. Howell Palliative Care Service, La Jolla, California, USA, 3University of California Department of Pediatrics, Rady Children's Hospital-San Diego, San Diego, California, USA, 4Millennium Research Institute, San Diego, California, USA, 5University of California Department of Pathology and Laboratory Medicine, San Diego, California, USA |
| 5. A novel diagnostic examination of the lumbar adhesion arachnoiditis by MRI scanning in supine and prone positions Kenji Azuma, Masahiko Sumitani, Takamichi Kogure, Hiroshi Sekiyama, Yoshitsugu Yamada Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan |
| 6. The conversion of hydrocodone to hydromorphone and norhydrocodone comparison in subjects with chronic pain Neveen Barakat1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5 1University of California, San Diego (UCSD), Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, LA Jolla, CA, USA |
| 7. Dose-proportionality, relative bioavailability, and effects of food on bioavailability of an immediate-release oxycodone HCl tablet designed to discourage tampering Almasa Bass1, Kenneth Somerville1, Robert Rolleri1, Glenn Pixton1, Jeffrey Stark2, Cynthia Zamora3, Mark Leibowitz3 1Pfizer Inc., Cary, NC, USA, 2Worldwide Clinical Trials Drug Development Solutions, Austin, TX, USA, 3Worldwide Clinical Trials Drug Development Solutions, San Antonio, TX, USA |
| 8. Daily average consumption of oxycodone CR and oxymorphone ER before and after the introduction of reformulated oxycodone CR R. Amy Puenpatom1, Kent Summers1, Robert Garvin1, Larry Ma1, Sheryl L. Szeinbach2, Rami Ben-Joseph1 1Endo Pharmaceuticals Inc., Chadds Ford, PA, USA, 2Ohio State University, College of Pharmacy, Columbus, OH, USA |
| 9. A viable methodology for assessing the onset of treatment for low back pain Jerrold Petrofsky1, Lee Berk1, Gurinder Bains1, Geraldine Doyle2, Shijie Chen2, Lisa Baird2, Paul Desjardins2, Jill Stark2 1Loma Linda University, Department of Physical Therapy, Loma Linda, CA, USA, 2Pfizer Consumer Healthcare, Madison, NJ, USA |
| 10. A posthoc pooled data analysis to evaluate the gastrointestinal tolerability profile of tapentadol extended release (ER) vs oxycodone controlled release (CR) in patients ≥75 years of age David Biondi1, Jim Xiang2, Mila Etropolski2, Bruce Moskovitz1 1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA |
| 11. A posthoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies David Biondi1, Jim Xiang2, Mila Etropolski2, Bruce Moskovitz1 1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA |
| 12. Treatment of painful diabetic peripheral neuropathy in the nursing home: prevalence of the disease and conformance with a new evidence-based guideline Frank Breve Mid Atlantic PharmaTech Consultants, LLC, Ventnor, New Jersey, USA |
| 13. Initial findings on abuse rates and routes of administration following introduction of reformulated OxyContin® in a sentinel surveillance system of patients in substance use treatment Theresa Cassidy1, Paul Coplan2, Ryan Black1, Howard Chilcoat2, Simon Budman1, Stephen Butler1 1Inflexxion, Inc., Newton, MA, USA, 2Purdue Pharma L.P., Stamford, CT, USA |
| 14. Sphygmomanometry-evoked allodynia for the identification of fibromyalgia patients Arthi Chandran1, Cheryl Coon2, Susan Martin2, Lori McLeod2, Theresa Gilligan2, Lesley Arnold3 1Pfizer Inc., New York, NY, USA, 2RTI Health Solutions, Ann Arbor, MI, USA, 3University of Cincinnati College of Medicine, Cincinnati, OH, USA |
| 15. An aid to guide primary care physicians in the differential diagnosis of fibromyalgia Lesley Arnold1, Arthi Chandran2, Susan Martin3 1University of Cincinnati College of Medicine, Cincinnati, OH, USA, 2Pfizer Inc., New York, NY, USA, 3RTI Health Solutions, Ann Arbor, MI, USA |
| 16. Evaluation of safety and efficacy of LEVADEX® (MAP0004) in treating acute menstrual migraine Curtis P. Schreiber1, Shashidhar H. Kori2, Sylvia M. Lucas3, Scott W. Borland2, Min Wang2, Bin Hu2, Jan L. Brandes4, Susy Chen2 1Headache Care Center, Primary Care Network, Springfield, MO, USA, 2MAP Pharmaceuticals, Inc., Mountain View, CA, USA, 3University of Washington Medical Center, Seattle, WA, USA, 4Nashville Neuroscience Group, PC, Nashville, TN, USA |
| 17. A long-term open-label study assessing the safety and tolerability of LEVADEX® orally inhaled dihydroergotamine in adult migraineurs Don Kellerman, Jean Chang, Shashidhar Kori, Susy Chen MAP Pharmaceuticals, Inc., Mountain View, CA, USA |
| 18. Pain Education School: findings from year one of an "informational healing" program David Cosio, Erica Hugo, Ronald Albrecht Anesthesiology Service/Pain Clinic, Jesse Brown VA Medical Center, Chicago, IL, USA |
| 19. An "informational" healing program: introduction to the Pain Education School program at Jesse Brown VA Medical Center David Cosio, Erica Hugo, Ronald Albrecht Anesthesiology Service/Pain Clinic, Jesse Brown VA Medical Center, Chicago, IL, USA |
| 20. The medical borderline: personality characteristics that promote increased risk of opioid misuse Geralyn Datz1, Melissa Bonnell2, Toni Merkey2, Todd Sitzman3 1Forrest General Hospital, Hattiesburg, MS, USA, 2University of Southern Mississippi, Hattiesburg, MS, USA, 3Advanced Pain Therapy, PLLC, Hattiesburg, MS, USA |
| 21. Test-Retest reliability of clinical sensory testing for sensorimotor polyneuropathy Joseph O. DiDuro, Thomas J. Burke Neuropathy Treatment Centers of America, Phoenix, AZ, USA |
| 22. A prospective study of changes in pain numeric rating scale with physiotherapy treatment for neuropathic pain Joseph O. DiDuro, Thomas Burke Neuropathy Treatment Centers of America, Phoenix, AZ, USA |
| 23. A randomized, double-blind, placebo-controlled discontinuation study of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment Philip Mease1, Yimin Ma2, Arlene Baldecchi2, Robert H. Palmer2, Joel M. Trugman2, Ian D'Souza2 1Seattle Rheumatology Associates and Swedish Medical Center, Seattle, Washington, USA, 2Forest Research Institute, Jersey City, New Jersey, USA |
| 24. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia Lesley Arnold1, Allan Spera2, Arlene Baldecchi2, Yong Wang2, Ian D'Souza2 1University of Cincinnati College of Medicine, Cincinnati, USA, 2Forest Research Institute, Jersey City, USA |
| 25. Assessing concomitant use of oxycodone formulations with known strong cytochrome P450 (CYP) 2D6 inhibitors in patients with chronic pain Natalie M. Elder1, Rabia S. Atayee1,2, Joseph D. Ma1,2, Bookie M. Best1,3, Amadeo J. Pesce4,5 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, La Jolla, CA, USA, 3University of California San Diego Department of Pediatrics; Rady's Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5University of California San Diego Department of Pathology, La Jolla, CA, USA |
| 26. Perceiving pain in oneself and others: the influence of perspective and priming Samantha R. Fashler1, Kalie N. McCrystal1, Daniel Jones1, Judith Versloot2, Kenneth D. Craig1 1University of British Columbia, Vancouver, BC, Canada, 2University of Toronto, Toronto, ON, Canada |
| 27. Perceiving pain in sports injuries: behavioral, contextual and cognitive factors Kalie N. McCrystal1, Samantha R. Fashler1, Judith Versloot2, Kenneth D. Craig1 1University of British Columbia, Vancouver, British Columbia, Canada, 2University of Toronto, Toronto, Ontario, Canada |
| 28. Prescription adherence among chronic pain patients: does monitoring according to the SAFE USE treatment monitoring program clinical guidelines for chronic opioid therapy improve patient adherence? B. Baker Fore1 1The Wellness Center, Ardmore, OK, USA, 2Mercy Memorial Hospital, Ardmore, OK, USA |
| 29. Participation in a regional hydromorphone safety initiative Maria Foy, Maria Doll Shaw, Robert Giannini Abington Memorial Hospital, Abington, PA, USA |
| 30. When is more too much? A case of opioid induced neurotoxity Maria Foy, Aalap Patel Abington Memorial Hospital, Abington, PA, USA |
| 31. Safety of diclofenac sodium topical solution compared with oral diclofenac for osteoarthritis of the knee in patients aged ≥65 years: pooled analysis from two controlled trials Sanford Roth1, Philip Fuller1 1Arizona State University, Phoenix, AZ, USA, 2Covidien, Hazelwood, MO, USA |
| 32. Efficacy of diclofenac sodium topical solution compared with oral diclofenac: a by-question analysis of 3 WOMAC ® dimensions in patients with osteoarthritis of the knee Sanford Roth1, Philip Fuller2 1Arizona State University, Phoenix, AZ, USA, 2Covidien, Hazelwood, MO, USA |
| 33. Assessment of chronic pain, impact on quality of life, and medication use utilizing a patient questionnaire Dean Gianarkis1, Beth Vanderheyden1, Scott E. Glosner1, Maureen L. Blattner2, Peggy Lotkowictz3, Therese Cardosi4 1Pfizer, Inc., New York, NY, USA, 2Arthritis Foundation, West Allis, Wisconsin, Upper Midwest Region, USA, 3Arthritis Foundation, Iselin, NJ, Northeast Region, USA, 4Arthritis Foundation, Kankakee, IL, USA |
| 34. Bioavailability of crush-resistant oxymorphone extended-release 40 mg with ethanol under fasted conditions William Fiske, Janet Jobes, Qinfang Xiang, Errol Gould, Irma Benedek Endo Pharmaceuticals Inc., Chadds Ford, PA, USA |
| 35. Bioequivalence of crush-resistant oxymorphone extended release 40 mg and oxymorphone extended release 40 mg under fed conditions Irma Benedek, Janet Jobes, Qinfang Xiang, Errol Gould, William Fiske Endo Pharmaceuticals Inc., Chadds Ford, PA, USA |
| 36. Effectiveness and safety of lidocaine 5% patch as add-on treatment in patients with allodynia caused by postherpetic neuralgia, diabetic neuropathy, or low back pain Srinivas Nalamachu1, Matthew S. Wieman2, Errol M. Gould2 1International Clinical Research Institute, Overland Park, KS, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, PA, USA |
| 37. Efficacy, safety, and tolerability of HZT-501, including users of low-dose aspirin (LDA), a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials Michael Weinblatt1, Mark Genovese2, Alan Kivitz3, Al Bello4, Amy Grahn5, Michael Schiff6 1Harvard Medical School Division of Rheumatology, Boston, MA, USA, 2Stanford University, Stanford, CA, USA, 3Altoona Center for Clinical Research, Altoona, PA, USA, 4Illinois Bone and Joint Institute, Glenview, IL, USA, 5Horizon Pharma USA, Inc, Northbrook, IL, USA, 6University of Colorado, Denver, CO, USA |
| 38. Long-term safety of an NSAID with built-in gastroprotection for treatment of pain and inflammation related to OA and RA: comparative results from blinded and open-label one- year safety trials of a single-tablet combination of ibuprofen-famotidine Jay Goldstein1, Sharad Lakhanpal2, Stanley Cohen2, Al Bello3, Amy Grahn4, Alan Kivitz5 1University of Illinois, Chicago, IL, USA, 2Metroplex Clinical Research Center, Dallas, TX, USA, 3Illinois Bone and Joint Institute, Morton Grove, IL, USA, 4Horizon Pharma USA, Inc, Northbrook, IL, USA, 5Altoona Center for Clinical Research, Altoona, PA, USA |
| 39. An innovative Risk Evaluation and Mitigation Strategy (REMS) for Abstral, a transmucosal immediate-release fentanyl (TIRF) product Greg Guillory1, Anthony G. Oladipo1, Bridget O'Mahony2, Kristina Crockett3, Julian Howell1 1ProStrakan, Inc., Bedminster, New Jersey, USA, 2ProStrakan Group Plc., Galashiels TD1 1QH, UK, 3RelayHealth Pharmacy, Atlanta, Georgia, USA |
| 40. Inter- and intrasubject variability of urinary norbuprenorphine to buprenorphine metabolic ratios in pain patients Alexander Y. Guo1, Rabia S. Atayee1,2, Joseph D. Ma1,2, Brookie M. Best1,3, Amadeo J. Pesce4,5 1University of California, San Diego, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA |
| 41. Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opioid-tolerant patients with chronic low back pain Martin Hale1, Srinivas Nalamachu2, Arif Khan3 1Gold Coast Research, LLC., Weston, FL, USA, 2International Clinical Research Institute, Overland Park, KS, USA, 3Northwest Clinical Research Center, Bellevue, WA, USA |
| 42. Perceived pain, disability, and psychometric measures in neuropathic vs nociceptive pain Meryem Saracoglu1,2, Joseph R. Graciosa1, Maxine M. Kuroda1, R. Norman Harden1,2 1Rehabilitation Institute of Chicago, Chicago, IL, USA, 2Northwestern University Feinberg School of Medicine, Department of Physical Medicine & Rehabilitation, Chicago, IL, USA |
| 43. Providing optimal care to the chronic pain patient in the community pharmacy: a patient survey Erron Swick, Chris Herndon Southern Illinois University Edwardsville, Edwardsville, IL, USA |
| 44. Knowledge of chronic pain: an analysis of health literacy Jake Griffin, Radhika Devraj, Chris Herndon Southern Illinois University Edwardsville, Edwardsville, IL, USA |
| 45. Oral local anesthesia successfully ameliorated neuropathic pain in an upper limb, suggesting pain alleviation through neural plasticity within the central nervous system: a case report Jun Hozumi1, Masahiko Sumitani1, Arito Yozu2, Toshiya Tomioka1, Hiroshi Sekiyama1, Satoru Miyauchi3, Yoshitsugu Yamada1 1Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Rehabilitation Medicine, The University of Tokyo, The Graduate School of Medicine, Tokyo, Japan, 3Kobe Advanced ICT Research Center, National Institute of Information and Communications Technology, Kobe, Japan |
| 46. Donepezil could reverse pregabalin/gabapentin-induced somnolence in patients with neuropathic pain Kiyoshi Ikegami1, Masahiko Sumitani1, Takamichi Kogure1, Kenji Azuma1, Hiroshi Sekiyama1, Satoru Miyauchi2, Yoshitsugu Yamada2 1Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, 2CREST brain function imaging team, Kobe Advanced ICT Research Center, National Institute of Information and Communications Technology, Hyogo, Japan |
| 47. Analysis of Pain Management Team patient survey Christine Kahley, Christine Higgins, Alisha Cain York Hospital, York, PA, USA |
| 48. Impact of an electronic medication error reporting system in a hospice organization Mina Kim1, Mary Lynn McPherson2, Elizabeth Kopochis3, Sheila Weiss2 1University of Washington Medical Center, Seattle, WA, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3Seasons Hospice and Palliative Care, Philadelphia, PA, USA |
| 49. Medication error reporting practices in hospice Mina Kim1, Mary Lynn McPherson1 1University of Washington Medical Center, Seattle, WA, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA |
| 50. Incidence of hydromorphone associated opioid-induced neurotoxicity Justin Kullgren1,2, Vy Le2, Warren Wheeler1 1Roseman University of Health Sciences, Henderson, NV, USA, 2Nathan Adelson Hospice, Las Vegas, NV, USA |
| 51. Comparison of oral fluid and urine drug testing in a population of those with chronic pain Sergey Latyshev, David Masters-Moore, Charles Mikel Millennium Research Institute, San Diego, CA, USA |
| 52. Using quantitative urine drug levels to monitor adherence to chronic opioid therapy: a comparison across two pain populations Russell Portenoy1, Harry Leider2, Ariel Linden3, Kathryn Bronstein2, Laura Dhingra1, Helena Knotkova1, Ricardo Cruciani1 1Beth Israel Medical Center, New York, NY, USA, 2Ameritox, Ltd., Baltimore, MD, USA, 3Linden Consulting Group, LLC, Portland, OR, USA |
| 53. Healthcare provider perspectives on managing pain in the geriatric population Salma Lemtouni1, Kevin Zacharoff2, Karen Weiss1, Synne Wing Venuti2, Pravin Pant2, Ryan Black2 1US Food and Drug Administration's Safe Use Initiative, Washington, DC, USA, 2Inflexxion, Inc., Newton, MA, USA |
| 54. The distribution of diazepam urinary metabolites in a sample of patients with chronic pain Samantha O. Luk1, Rabia S. Atayee1,2, Joseph D. Ma1,2, Brookie M. Best1,3, Amadeo J. Pesce4,5 1University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA |
| 55. A survey of ambulatory care pharmacist's perceptions and use of state controlled substance registries Karen Marlowe1,2, Emily MCCoy1,2 1Auburn University, Auburn, AL, USA, 2University of South Alabama, Mobile, AL, USA |
| 56. Update on the safety of pharmaceutical-grade dimethyl sulfoxide as a penetration enhancer for diclofenac sodium topical solution Jeffrey Patrick, Karrie Marren Covidien, Hazelwood, MO, USA |
| 57. Provider adherence to an institution-wide opioid therapy policy for patients with chronic noncancer pain in the primary care setting Michele Matthews1,2, Alexander Tinios1, Robert Jamison2, Edgar Ross2, Lori Tishler2 1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Brigham and Women's Hospital, Boston, MA, USA |
| 58. Lifestyle Redesign® for Chronic Headaches Susan McNulty, Soma Sahai-Srivastava University of Southern California, Los Angeles, CA, USA |
| 59. Will the FDA's REMS for opioids become an Emerging Solution in Pain (ESP)? Bronwyn Boyes, Joan Meyer MediCom Worldwide, Inc., Morrisville, PA, USA |
| 60. Effectiveness of nonpharmacological/noninterventional CBT based treatment for chronic pain Rick F. Meyers1, Kathy Savicki2, Janice Veehuizen1,2, Ed Daly1, Steven-Tackett Nelson1, Rebecca Ricoy1 1Mid-Valley Pain Clinic, Salem, OR, USA, 2Behavioral Care Network, Salem, OR, USA, 3Oregon Health and Sciences University, Portland, OR, USA |
| 61. A correlative study of the self-reported Ratings Determining Impairment Associated with Pain, from the AMA Guides Fifth Edition, and the clinician-derived Physical Performance Tests on Individuals with polytrauma history and with chronic pain: case series Armando Miciano1, Jacqueline Derhousoff1, Chad Cross2 1Nevada Rehabilitation Institute, Las Vegas, NV, USA, 2University of Nevada, Las Vegas, NV, USA |
| 62. Direct medical costs of opioid management and the functional status of subjects with polytrauma history >two years and chronic noncancer pain: impact on healthcare utilization and life care planning Armando Miciano Nevada Rehabilitation Institute, Las Vegas, NV, USA |
| 63. Quantification of skeletal muscle mass by Bioelectric Impedance Analysis in elderly individuals with chronic nonmalignant pain and in asymptomatic individuals and its relationships among impairments in gait and balance, functional limitations, and disability Armando Miciano Nevada Rehabilitation Institute, Las Vegas, NV, USA |
| 64. The functional status due to Pain-Related Impairments, according to the AMA Guides Sixth Edition, and the physical performance status of subjects with a >two-year polytrauma history and with a spine impairment: a descriptive case study Armando Miciano1, Chad Cross1 1Nevada Rehabilitation Institute, Las Vegas, NV, USA, 2University of Nevada, Las Vegas, NV, USA |
| 65. Determining the functional status, according to the AMA Guides Sixth Edition, Pain-Related Impairment, and physical performance of community-dwelling adults with osteopenia and with lower extremity pain Armando Miciano Nevada Rehabilitation Institute, Las Vegas, NV, USA |
| 66. Direct medical costs of pain specialist visits, the multimorbidity burden, pain-related impairment, and the physical performance on subjects with polytrauma history >two years and chronic nonmalignant pain: impact on life care planning Armando Miciano Nevada Rehabilitation Institute, Las Vegas, NV, USA |
| 67. Occipital nerve radiofrequency ablation for occipital neuralgia and associated headaches: report of two special medical condition cases Rafael Miguel, Christopher Russo Pain Medicine Program, Department of Neurology, University of South Florida, Tampa, Florida, USA |
| 68. Therapeutic monitoring of benzodiazepines in the population of patients treated for pain: current limitations of inoffice immunoassays necessitate testing by mass spectrometry to assure accuracy Charles Mikel, Murray Rosenthal, Amadeo Pesce Millennium Research Institute, San Diego, CA, USA |
| 69. Pain Paradox: clinician judgment for assessment and management of risks in chronic opioid therapy James Miller1, Howard A. Heit2, Douglas Gourlay3, John F. Peppin4, Carol Hampton5, Susan E. Miller1 1Educational Awareness Solutions, Norwalk, CT, USA, 2Georgetown School of Medicine, Fairfax, VA, USA, 3Wasser Pain Management Center, Mount Sinai Hospital, Toronto, ON, Canada, 4The Pain Treatment Centers of the Bluegrass, Lexington, KY, USA, 5Research and Outcomes Institute, South Norwalk, CT, USA |
| 70. Breakthrough cancer pain in patients treated with fentanyl sublingual tablets: posthoc analyses of treatment response Srinivas Nalamachu1, Richard L. Rauck2, Ann Yellowlees3, Greg Guillory4, Julian Howell4 1Mid America Physiatrists, PA, Leawood, Kansas, USA, 2Carolinas Pain Institute Center for Clinical Research, Winston-Salem, North Carolina, USA, 3Quantics Consulting Ltd, Roslin EH25 9TT, UK, 4ProStrakan, Inc., Bedminster, New Jersey, USA |
| 71. Efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain: a pooled analysis of two studies Srinivas R. Nalamachu1, Arvind Narayana2, Craig Q. Earl2, Ronghua Yang2, Mark S. Wallace3 1Mid-America Physiatrists, Overland Park, KS, USA, 2Cephalon, Inc., Frazer, PA, USA, 3University of California, San Diego, School of Medicine, La Jolla, CA, USA |
| 72. The National Breakthrough Pain Survey (NBTPS): assessment of quality of life, functioning, and productivity Arvind Narayana1, Nathaniel Katz2,3, Alicia C. Shillington4, Russell K. Portenoy5 1Cephalon, Inc., Frazer, PA, USA, 2Tufts University School of Medicine, Boston, MA, USA, 3Analgesic Solutions, Natick, MA, USA, 4EPI-Q, Inc., Oak Brook, IL, USA, 5Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY, USA |
| 73. Aberrant drug-related behavior observed during a 12-week open-label study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain Steven D. Passik1, Craig Q. Earl2, Ronghua Yang2 1Vanderbilt University Medical Center, Nashville, TN, USA, 2Cephalon, Inc., Frazer, PA, USA |
| 74. Exploring the economic impact of a pre-evaluation unit in a multidisciplinary pain clinic Kenneth L. Kirsh1, Peter Wright1,2, John F. Peppin1,2 1The Pain Treatment Center of the Bluegrass, Lexington, Kentucky, USA, 2Hospice of the Bluegrass, Lexington, Kentucky, USA, 3The University of Kentucky, Lexington, Kentucky, USA |
| 75. Functional assessment of chronic pain patients in a multidisciplinary pain clinic John F. Peppin1,2, Steve Marcum4, Ashley Baughn3, Kenneth L. Kirsh3 1The Pain Treatment Center of the Bluegrass, Clinical Research Division, Lexington, Kentucky, USA, 2Hospice of the Bluegrass, Lexington, Kentucky, USA, 3The Pain Treatment Center of the Bluegrass, Behavioral Medicine, Lexington, Kentucky, USA, 4The Pain Treatment Center of the Bluegrass, Physical Therapy Department, Lexington, Kentucky, USA |
| 76. Effect of age and sex on the pharmacokinetics and metabolism of oxymorphone extended-release tablets Joseph V. Pergolizzi1, Matthew S. Wieman2, Errol M. Gould2 1Naples Anesthesia and Pain Associates, Naples, FL, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, PA, USA |
| 77. Safety of oxymorphone extended release with selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors John H. Peniston1, Susan Potts2, Xiaojun Hu2, Matthew S. Wieman2 1Feasterville Family Health Care Center, Jamison, PA, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, PA, USA |
| 78. Oxymorphone extended release in patients with depression John H. Peniston1, Susan Potts2, Xiaojun Hu2, Matthew S. Wieman2 1Feasterville Family Health Care Center, Jamison, PA, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, PA, USA |
| 79. Effectiveness of a heated lidocaine/tetracaine topical patch in reducing pain intensity and pain interference associated with myofascial trigger points: results of an open-label pilot study Richard Rauck1, Michael Busch2, Thomas Marriott2, Michael Smith2, James Heusner2 1Carolinas Pain Institute, Winston-Salem, NC, USA, 2ZARS Pharma, Salt Lake City, UT, USA |
| 80. A model to identify patients at risk for prescription opioid abuse, dependence, and misuse J. Bradford Rice1, Alan G. White1, Howard G. Birnbaum1, Matthew B. Schiller1, David A. Brown2, Carl L. Roland2 1Analysis Group, Boston, MA, USA, 2Pfizer, Inc., Cary, NC, USA |
| 81. Safety and efficacy of once-daily hydromorphone ER (OROS hydromorphone ER) compared with twice-daily oxycodone CR over 52 weeks in patients with moderate to severe chronic noncancer pain Ute Richarz1, Sandra Waechter1, Rainer Sabatowski2, Leszek Szczepanski3, Heinrich Binsfeld4 1Janssen-Cilag, Baar, Switzerland, 2University Hospital Carl Gustav Carus, Technical University, Dresden, Germany, 3Wyzsza Szkola Zarzadzania i Administracji, Zamosc, Poland, 4Schmerz-Zentrum am St. Franziskus Hospital Ahlen, Ahlen, Germany |
| 82. Assessing a new educational strategy to improve postoperative pain management after discharge Gary A. Rich Adherent Health, Doylestown, PA, USA |
| 83. Physician risk assessment for opioid therapy in patients with chronic pain: results from a national survey Gregory Salinas1, Jill Foster1, Stephen Burton1, Nancy Roepke1, Debi Susalka1, Kimberly Evanyo2 1CE Outcomes, LLC, Birmingham, AL, USA, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA |
| 84. Clinician/patient interactions and counseling on opioid use: results from a national survey Gregory Salinas1, Jill Foster1, Stephen Burton1, Nancy Roepke1, Debi Susalka1, Kimberly Evanyo2 1CE Outcomes, LLC, Birmingham, AL, USA, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA |
| 85. Concurrent quantification of itch sensation and pain in patients with postherpetic neuralgia by PainVision Hiroshi Sekiyama1, Kazuo Hanaoka1,2, Takamichi Kogure1, Kenji Azuma1, Masahiko Sumitani1, Yoshitsugu Yamada1 1Department of Anesthesiology, University of Tokyo, Tokyo, Japan, 2Department of Anesthesiology, Tokyo, Japan |
| 86. Assessing the abuse potential of crushed EMBEDA® compared to crushed morphine sulfate controlled-release tablets and placebo in nondependent, recreational opioid users following intranasal administration Beatrice Setnik1, Jody Cleveland1, Veeraindar Goli1, Naama Levy-Cooperman2, Ira Smith2 1Pfizer Inc., Cary, NC, USA, 2Kendle Early Phase, Toronto, ON, Canada |
| 87. Self reports of prescription opioid misuse, abuse and diversion in a sample of chronic pain patients treated in primary care settings: preliminary findings Beatrice Setnik, David Brown, Carl Roland Pfizer Inc., Cary, NC, USA |
| 88. A biomarker panel to assess depression in pain patients Joseph Shurman1, George Koob2, Rosa Navarro3, Brett Shurman5, Katie Smith4, John Bilello4 1Scripps Memorial Hospital, San Diego, CA, USA, 2Scripps Research Institute, LaJolla, CA, USA, 3Navarro Pain Control Group, Inc., San Diego, CA, USA, 4Ridge Diagnostics, Inc, San Diego, CA, USA, 512401 Wilshire Blvd, Los Angeles, CA, USA |
| 89. Ischemic ulcer pain includes not only nociceptive pain but neuropathic pain components, based on a discriminant function analysis using McGill Pain Questionnaire Takamichi Kogure1, Masahiko Sumitani1, Arito Yozu2, Hironobu Uematsu3, Satoru Miyauchi4, Yoshitsugu Yamada1 1Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Rehabilitation Medicine, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, 3Department of Acute Critical Medicine (Anesthesiology), Osaka University, Graduate School of Medicine, Osaka, Japan, 4Kobe Advanced ICT Research Center, National Institute of Communications and Technology, Kobe, Japan |
| 90. Prevalence of CYP450 drug-drug exposures among oxycodone CR patients Joseph V. Pergolizzi1, Sumedha Labhsetwar2, Kent Summers3, R. Amy Puenpatom3, Rami Ben-Joseph3, Chunmay Fu3 1Naples Anesthesia and Pain Associates, Naples, FL, USA, 2Nema Research Inc., Naples, FL, USA, 3Endo Pharmaceuticals Inc., Chadds Ford, PA, USA |
| 91. Comparison of ECG and Holter monitoring QTc interval measurements in patients with increased risk for QTc prolongation Arun Sundaram1, Arash Nafissi3, Paul Schweitzer1, Ella Dvorkin1, Peter Homel1, Daniel Feldman1, Russell Portenoy1,2, Ricardo Cruciani1,2 1Dept Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York, USA, 2Dept Neurol & Anesth, Albert Einstein College of Medicine, Bronx, New York, USA, 3Dept P&MR, New York University, New York, New York, USA |
| 92. Usability of an experiential course to educate medical students in proper use of opioids in the treatment of pain Bradley Tanner, Mary Metcalf, Susan Wilhelm Clinical Tools, Inc, Chapel Hill, NC, USA |
| 93. Improvement in sleep maintenance and early morning awakenings in adult and elderly patients with insomnia treated with doxepin 3 and 6 mg Robert Taylor1, Joseph Pergolizzi2, H Heith Durrence3, Brian Dorsey3, Roberta Rogowski1, Thomas Roth1 1NEMA Research Inc., Naples, FL, USA, 2Johns Hopkins University School of Medicine, Baltimore, MD, USA, 3Somaxon Pharmaceuticals, San Diego, CA, USA, 4Henry Ford Sleep Disorders Center, Detroit, MI, USA |
| 94. Consistency of symptom improvement in elderly adults with chronic insomnia treated with doxepin 1 mg, 3 mg, and 6 mg Robert Taylor1, Joseph Pergolizzi2, H Heith Durrence3, Roberta Rogowski3, Thomas Roth4 1NEMA Research Inc, Naples, FL, USA, 2Johns Hopkins University School of Medicine, Baltimore, MD, USA, 3Somaxon Pharmaceuticals, San Diego, CA, USA, 4Henry Ford Sleep Disorders Center, Detroit, MI, USA |
| 95. Topical corticosteroid administration by pulsed radiofrequency energy Forest Tennant Veract Intractable Pain Clinic, West Covina, CA, USA |
| 96. Chorionic gonadotropin initial doses for intractable pain Forest Tennant Veract Intractable Pain Clinic, West Covina, CA, USA |
| 97. Endocrine findings and serum opioid levels after 20 years of therapy Forest Tennant Veract Intractable Pain Clinic, West Covina, CA, USA |
| 98. Weekly response following a single administration of Qutenza®, an 8% capsaicin patch, in patients with postherpetic neuralgia: results of integrated analyses Lynn R. Webster1, Gordon Irving2, Miroslav Backonja1, Jeffrey Tobias3, Geertrui F. Vanhove3 1LifeTree Clinical Research, Salt Lake City, UT, USA, 2Swedish Pain Center, Seattle, WA, USA, 3NeurogesX, San Mateo, CA, USA |
| 99. Factors that may affect carisoprodol metabolism by cytochrome P450 (CYP) 2C19 in pain patients using urinary excretion data Stephanie Tse1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5 1University of California, San Diego (UCSD), Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, >4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA |
| 100. A repeat-dose, steady-state pharmacokinetic evaluation of once-daily hydromorphone ER (OROS hydromorphone ER) in patients with chronic cancer or noncancer pain Joris Vandenbossche1, Ute Richarz2, Henry Richards3 1Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium, 2Janssen-Cilag, Baar, Switzerland, 3Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA |
| 101. Characterization of the pharmacokinetic profile of single-dose once-daily hydromorphone ER (OROS hydromorphone ER) vs IR hydromorphone administered over 24 hours in healthy subjects Ute Richarz1, Joris Vandenbossche2, Michael Kutch3, Todd Moore4 1Janssen-Cilag, Baar, Switzerland, 2Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium, 3Applied Clinical Intelligence, Bala Cynwyd, PA, USA, 4Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA |
| 102. Characterization of the steady-state pharmacokinetic profile of once-daily hydromorphone ER (OROS hydromorphone ER) vs IR hydromorphone in healthy subjects Ute Richarz1, Joris Vandenbossche2, Michael Kutch3, Todd Moore4 1Janssen-Cilag, Baar, Switzerland, 2Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium, 3Applied Clinical Intelligence, Bala Cynwyd, PA, USA, 4Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA |
| 103. TD-1211 demonstrates peripheral selectivity and constipation-relieving effects in patients with opioid-induced constipation Ross Vickery1, Yu-Ping Li1, Roger Kohler1, Lynn Webster2, Neil Singla3, Oranee Daniels1 1Theravance, Inc., South San Francisco, CA, USA, 2Lifetree Clinical Research, Inc., Salt Lake City, UT, USA, 3Lotus Clinical Research, Inc., Pasadena, CA, USA |
| 104. The impact of health literacy on chronic pain Julie Waldfogel, Meredith Adams, Robert Hurley University of Florida, Gainesville, Florida, USA |
| 105. Butrans® (buprenorphine) transdermal system (BTDS) improves health-related quality of life in patients with moderateto-severe chronic low back pain Aaron Yarlas1, Warren Wen2, Maribeth Kowalski2, Shau Yu Lynch2, Bradley Dain2, Steven Ripa2 1QualityMetric, Inc., Lincoln, RI, USA, 2Purdue Pharma LP, Stamford, CT, USA |
| 106. Butrans® (buprenorphine) Transdermal System (BTDS) improves sleep quality and reduces sleep problems in patients with moderate-to-severe chronic low back pain Aaron Yarlas1, Warren Wen2, Maribeth Kowalski2, Shau Yu Lynch2, Bradley Dain2, Steven Ripa2 1QualityMetric, Inc., Lincoln, RI, USA, 2Purdue Pharma LP, Stamford, CT, USA |
| 107. Observations on the urinary metabolic profile of codeine in patients with chronic pain David Yee1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5 1University of California, San Diego (UCSD), Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA |
| 108. painACTION.com: Web-based support to self-manage neuropathic pain Kevin Zacharoff, Jonas Bromberg, Synne Venuti, Mollie Wood, Dan Surette Inflexxion, Inc., Newton, MA, USA |
| 109. Survey of healthcare providers on clinical technology and transition to electronic opioid risk assessments K.L. Zacharoff, S.F. Butler, M. Wood, S. Charity, S. Budman Inflexxion, Inc, Newton, MA, USA |
| 110. Pharmacokinetic interaction between the opioid-analgesic fentanyl and the CYP3A inhibitor ketoconazole Victoria Ziesenitz1, Sonja Koenig1, Nina Mahlke2, Gisela Skopp2, Juergen Burhenne1, Gerd Mikus1 1Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany, 2Institute of Legal Medicine, University of Heidelberg, Heidelberg, Germany |
| 111. Observations of oxycodone coprescriptions and nonreported prescription medications in a population of those with chronic pain Elizabeth Gonzales, Murray Rosenthal, Amadeo Pesce, Charles Mikel, Robert West, Cameron West, Sergey Latyshev, Perla Almazan Millennium Research Institute, San Diego, USA |
| 112. Variability of meperidine metabolism and excretion in patients with chronic pain Kathleen Moy1, Rabia Atayee1,2, Joseph Ma1,2, Brookie Best1,3, Amadeo Pesce4,5 1University of California San Diego (UCSD), Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA, 2Doris A. Howell Palliative Care Service, San Diego, CA, USA, 3UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, 4Millennium Research Institute, San Diego, CA, USA, 5Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA |
